Showing papers in "The Lancet in 2021"
••
University of Oxford1, Federal University of São Paulo2, University of the Witwatersrand3, Stellenbosch University4, Liverpool School of Tropical Medicine5, University of Sheffield6, University of London7, Newcastle upon Tyne Hospitals NHS Foundation Trust8, University Hospital Southampton NHS Foundation Trust9, University Hospitals Bristol NHS Foundation Trust10, Guy's and St Thomas' NHS Foundation Trust11, University Hospitals Birmingham NHS Foundation Trust12, St George's, University of London13, AstraZeneca14, North Bristol NHS Trust15, University College Hospital16, University of Hull17, Escola Bahiana de Medicina e Saúde Pública18, Federal University of Rio Grande do Norte19, Northwest University (China)20, Universidade Federal de Santa Maria21, Glasgow Dental Hospital and School22, Boston Children's Hospital23, Universidade Federal do Rio Grande do Sul24, Western General Hospital25, University of Glasgow26, Cambridge University Hospitals NHS Foundation Trust27, University of Cambridge28, Nottingham University Hospitals NHS Trust29, Aneurin Bevan University Health Board30
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
3,741 citations
••
TL;DR: In this article, the authors describe the long-term health consequences of patients with COVID-19 who have been discharged from hospital and investigate the associated risk factors, in particular disease severity.
2,933 citations
••
TL;DR: In this paper, the authors conducted a systematic review of data reporting the prevalence of major depressive disorder and anxiety disorders during the COVID-19 pandemic and published between Jan 1, 2020, and Jan 29, 2021.
1,582 citations
••
TL;DR: Gam-COVID-Vac (Sputnik V) showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials as discussed by the authors.
1,251 citations
••
TL;DR: In this article, the real-world effectiveness of two doses of BNT162b2 against a range of SARS-CoV-2 outcomes and to evaluate the nationwide public-health impact following the widespread introduction of the vaccine was estimated.
1,242 citations
••
Bin Zhou1, Rodrigo M. Carrillo-Larco1, Goodarz Danaei2, Leanne M. Riley2 +1141 more•Institutions (5)
TL;DR: In this article, a Bayesian hierarchical model was used to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control).
918 citations
••
University College London1, International Institute for Applied Systems Analysis2, University of Reading3, United Nations University4, University of London5, University of Colorado Boulder6, Umeå University7, Tsinghua University8, World Health Organization9, Cardiff University10, University of Geneva11, University of New England (United States)12, University of Birmingham13, Yale University14, University of Washington15, Northeastern University16, Virginia Tech17, University of Oxford18, University of York19, International Livestock Research Institute20, Cayetano Heredia University21, Harvard University22, Boston University23, University of Sussex24, Nelson Marlborough Institute of Technology25, Emory University26, Columbia University27, Autonomous University of Barcelona28, Technische Universität München29, University of Melbourne30, Iran University of Medical Sciences31, University of Exeter32, Imperial College London33, University of Sheffield34, European Centre for Disease Prevention and Control35, Universiti Malaysia Terengganu36, University of Santiago de Compostela37
TL;DR: TRANSLATIONS For the Chinese, French, German, and Spanish translations of the abstract see Supplementary Materials section.
886 citations
••
TL;DR: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.
862 citations
••
Cornell University1, Memorial Sloan Kettering Cancer Center2, University of Mainz3, Peking University4, Japanese Foundation for Cancer Research5, Medical University of Lublin6, Fudan University7, University of La Frontera8, Université de Montréal9, National and Kapodistrian University of Athens10, St John of God Murdoch Hospital11, Harvard University12, Bristol-Myers Squibb13, University of Texas MD Anderson Cancer Center14
TL;DR: The CheckMate 649 trial as discussed by the authors evaluated first-line programmed cell death (PD)-1 inhibitor-based therapies in gastric, gastro-oesophageal junction, and oesophage alogaryal adenocarcinoma.
858 citations
••
TL;DR: In this paper, the overall and variant-specific effectiveness of BNT162b2 (tozinameran, Pfizer BioNTech) against SARS-CoV-2 infections and COVID-19-related hospital admissions by time since vaccination among members of a large US health-care system was evaluated.
855 citations
••
••
TL;DR: The authors in this article reviewed potential challenges to success in each of these dimensions and discussed policy implications. But having licensed vaccines is not enough to achieve global control of COVID-19: they also need to be produced at scale, priced affordably, allocated globally so that they are available where needed, and widely deployed in local communities.
••
••
TL;DR: In this article, the authors used the data repositories of Clalit Health Services to evaluate the effectiveness of a third dose of the BNT162b2 mRNA vaccine for preventing severe COVID-19 outcomes.
••
TL;DR: In this paper, a global prevalence of 25% and is a leading cause of cirrhosis and hepatocellular carcinoma, and the leading causes of death in people with NAFLD are cardiovascular disease and extrahepatic malignancy.
••
Hacettepe University1, Turkish Ministry of Health2, Yıldırım Beyazıt University3, Ankara University4, Kocaeli University5, İzmir University6, Uludağ University7, Istanbul University8, Ege University9, Akdeniz University10, Acıbadem University11, Çukurova University12, Marmara University13, Karadeniz Technical University14, Dicle University15, İnönü University16, University of Gaziantep17
TL;DR: CoronaVac as discussed by the authors has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2.
••
••
TL;DR: The SIREN study as discussed by the authors showed that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infection in working-age adults in the UK.
••
TL;DR: Wang et al. as discussed by the authors conducted an ambidirectional cohort study of COVID-19 survivors who had been discharged from Jin Yin-tan Hospital (Wuhan, China) between Jan 7 and May 29, 2020.
••
Leiden University1, university of lille2, University of Western Australia3, University of Lausanne4, University of Texas MD Anderson Cancer Center5, Mayo Clinic6, The Royal Marsden NHS Foundation Trust7, University of California, San Francisco8, Erasmus University Rotterdam9, Aix-Marseille University10, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico11, Bristol-Myers Squibb12, Claude Bernard University Lyon 113
TL;DR: The CheckMate 743 trial as mentioned in this paper showed that nivolumab plus ipilimumab significantly improved overall survival compared to standard-of-care chemotherapy for non-small-cell lung cancer.
••
TL;DR: In this paper, the authors investigated the degree to which infection with SARS-CoV-2 confers protection against subsequent reinfection, and estimated protection against repeat infection.
••
University of Oxford1, Wellcome Trust Sanger Institute2, University of Cambridge3, Public Health England4, Liverpool School of Tropical Medicine5, University of Sheffield6, Newcastle University7, Newcastle upon Tyne Hospitals NHS Foundation Trust8, University Hospital Southampton NHS Foundation Trust9, University of Southampton10, University Hospitals Bristol NHS Foundation Trust11, St George's, University of London12, Guy's and St Thomas' NHS Foundation Trust13, University College London14, University Hospitals Birmingham NHS Foundation Trust15, University of Glasgow16, North Bristol NHS Trust17, University College Hospital18, University of Hull19, Northwest University (China)20, Glasgow Dental Hospital and School21, Western General Hospital22, University of Nottingham23, Nottingham University Hospitals NHS Trust24, AstraZeneca25, Cardiff University26, Aneurin Bevan University Health Board27
TL;DR: A post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against B.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020 as discussed by the authors.
••
Sarah Cannon Research Institute1, Mount Sinai Hospital2, University of Chicago3, University of Pittsburgh4, University of Pennsylvania5, Princess Margaret Cancer Centre6, Medical College of Wisconsin7, City of Hope National Medical Center8, Memorial Sloan Kettering Cancer Center9, Wayne State University10, Harvard University11, Beth Israel Deaconess Medical Center12, Janssen Pharmaceutica13, Mayo Clinic14, University of California, San Francisco15
TL;DR: The CARITUDE-1 trial as discussed by the authors evaluated the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies.
••
TL;DR: The SARS-CoV-2 Immunity and Reinfection Evaluation study as mentioned in this paper showed that a previous history of SARS infection was associated with an 84% lower risk of infection, with median protective effect observed 7 months following primary infection.
••
University College London1, University of Reading2, University of York3, United Nations University4, University of London5, Tsinghua University6, World Health Organization7, Cardiff University8, Yale University9, University of Birmingham10, University of Greenwich11, University of Washington12, Northeastern University13, Virginia Tech14, International Livestock Research Institute15, National University of Singapore16, Cayetano Heredia University17, Harvard University18, International Institute for Applied Systems Analysis19, Boston University20, University of Sussex21, Nelson Marlborough Institute of Technology22, Emory University23, Columbia University24, Autonomous University of Barcelona25, Technische Universität München26, University of Melbourne27, University of Copenhagen28, Iran University of Medical Sciences29, Technical University of Denmark30, Umeå University31, Max Planck Society32, University of Colorado Boulder33, University of Exeter34, University of Oxford35, Universiti Malaysia Terengganu36, University of Santiago de Compostela37, University of Hong Kong38
TL;DR: The 2021 report of the Lancet Countdown on health and climate change : code red for a healthy future as mentioned in this paper, is the most recent publication of the Countdown on Health and Climate Change, 2019.
••
TL;DR: In this paper, the authors evaluated the effects ofcilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation, and found that the drug improved survival and other clinical outcomes.
••
TL;DR: The biopsychosocial model of chronic pain this paper presents physical symptoms as the denouement of a dynamic interaction between biological, psychological, and social factors, which can be classified as nociceptive (from tissue injury), neuropathic (from nerve injury), or nociplastic (from a sensitised nervous system).
••
Samsung Medical Center1, Peking University2, Cornell University3, Harvard University4, University of Montpellier5, Shanghai Jiao Tong University6, University of Ulsan7, Yonsei University8, Chang Gung University9, Prince of Songkla University10, Universidade Federal de Santa Maria11, Roswell Park Cancer Institute12, Kagawa University13, Merck & Co.14
TL;DR: In this paper, the authors compared pembrolizumab plus chemotherapy versus chemotherapy alone as a first-line treatment for advanced oesophageal cancer and Siewert type 1 gastro-oesophagesphageal junction cancer.
••
TL;DR: The IMpower010 trial as mentioned in this paper evaluated adjuvant atezolizumab versus best supportive care (observation and regular scans for disease recurrence) in patients with early-stage non-small-cell lung cancer.